Abstract: PO2386
Decreased Progression of CKD in Patients Undergoing Fecal Microbiota Transplantation (FMT)
Session Information
- CKD: Insights from Recent Clinical Trials and Large Real-World Effectiveness Studies
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Arteaga Muller, Giovanna Y., Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Camacho-Ortiz, Adrian, Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Garza-Gonzalez, Elvira, Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Flores-Treviño, Samantha M., Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Bocanegra-Ibarias, Paola, Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Fabela-Valdez, Graciela Catalina, Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
- Rodriguez-Arroyo, Norma Yaravi, Hospital Universitario Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background
Prevalence of CKD is 8 to 16% in different stages, considered the main cause of emergency and hospital care in Mexico and catastrophic disease, its main causes: diabetes, arterial hypertension and glomerulonephritis. Treatment to prevent progression consists of inhibitors of the renin angiotensin aldosterone system, control of the underlying disease and blood pressure. The estimate of the loss of glomerular filtration rate is 2.3 to 4.5 ml/min per year in CKD patients. The intestinal microbiota has protective, structural and metabolic functions, there is a bidirectional interference of the microbiota and the host maintaining a symbiotic relationship, in CKD patients uremia affects the composition and metabolism of the microbiota, generating dysbiosis that is the absence of balance in the microbiological community generating an increase in the progression of CKD and an increase in the production of N-trimethylamine oxide, indoxyl sulfate and p-cresol sulfate associated with greater cardiovascular events in CKD patients, FMT has been used to correct dysbiosis in some pathologies.
Methods
A prospective, randomized, double-blind, comparative, placebo-controlled clinical trial, carried out at the University Hospital in Monterrey Mexico, in patients diagnosed with CKD due to diabetes and or hypertension, in stages 2, 3, 4 and 5 without renal replacement therapy, divided into 2 groups, MFT group: Microbiota fecal capsules, placebo group: placebo capsules, in both groups 15 capsules were administered every 12 hours for 2 days, on days 0, 10, 30, with a 6-month follow-up to demonstrate the difference in the progression of renal failure.
Results
28 patients were randomized, the CKD of the placebo group progressed by 53.8% vs 13.3% of the TMF group Fisher's exact test p value = 0.0418 (Table 1).
Conclusion
The difference in the proportion of patients who did not decrease their GFR at 6 months was statistically significant, in the present study the patients who received FMT had less progression of CKD at 6 months. FMT was associated with a protective factor.
Funding
- Private Foundation Support